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Abstract: The Urological Association of Asia, consisting of 25 member associations
and one affiliated member since its foundation in 1990, has planned to develop Asian
guidelines for all urological fields. The field of stone diseases is the third of its guideline
projects. Because of the different climates, and social, economic and ethnic
environments, the clinical practice for urinary stone diseases widely varies among the
Asian countries. The committee members of the Urological Association of Asia on the
clinical guidelines for urinary stone disease carried out a surveillance study to better
understand the diversity of the treatment strategy among different regions and
subsequent systematic literature review through PubMed and MEDLINE database
between 1966 and 2017. Levels of evidence and grades of recommendation for each
management were decided according to the relevant strategy. Each clinical question and
answer were thoroughly reviewed and discussed by all committee members and their
colleagues, with suggestions from expert representatives of the American Urological
Association and European Association of Urology. However, we focused on the
pragmatic care of patients and our own evidence throughout Asia, which included
recent surgical trends, such as miniaturized percutaneous nephrolithotomy and
endoscopic combined intrarenal surgery. This guideline covers all fields of stone
diseases, from etiology to recurrence prevention. Here, we present a short summary of
the first version of the guideline – consisting 43 clinical questions – and overview its key
practical issues.
Key words: grade recommendation, guideline, level of evidence, urolithiasis, Urological
Association of Asia.
Introduction
Aims and scope
Asia is the largest continent and accounts for approximately 60% of the world’s population.
The UAA includes many countries with diverse backgrounds in medicine, climate, insurance
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systems, equipment, and access to hospitals and facilities. We are required to establish a con-
sensus on treatment. The UAA Clinical Guidelines for Stone Disease have been prepared to
help urologists apply evidence-based management to stones/calculi and incorporate recom-
mendations into clinical practice. The document covers most aspects of the disease, which is
still a cause of significant morbidity despite technological and scientific advances. The Work
Group is aware of the geographical variations in the provision of healthcare. Diverse
treatment alternatives might be possible depending on the social environment of the relevant
case(s); however, the best treatment also depends on the circumstances of each individual
case and is not uniform. This guideline aims to obtain a consensus on the treatment approach
for urinary stone disease. The entire version of this guideline is available on the UAA web-
site. Here, we present a short summary of the first version of the guideline and overview its
key practical issues.
Diversity of treatment strategies among the UAA
Due to the different climates, and social, economic and ethnic environments, there is huge
diversity in clinical practice for urinary stone disease among Asian countries. Table 1 summa-
rizes treatment strategies for each UAA representative for different stone cases. In accordance
with other guidelines, SWL and endoscopic lithotomy, such as RIRS, URS and PCNL are
preferred choices in Asia; however, some countries in the Middle East and Southeastern Asia
still apply open/laparoscopic pyelolithotomy and ureterolithotomy as surgical options for treat-
ment of renal staghorn and ureteral impacted stones, respectively. Another interesting treat-
ment option often chosen in Korea, Japan and Turkey is ECIRS. For pediatric renal stone
cases, SWL is still the standard in the majority of the associations, but RIRS and minimally
invasive PCNL are also accepted as reasonable options.
Methods
Data identification
The Guideline for Stone Diseases was developed by committee members recommended by
the UAA. The members meticulously reviewed the relevant references retrieved via the
PubMed and MEDLINE databases published between 1966 through 31 July 2017.
The search strategy included the following medical subject headings (MeSH) for stone dis-
eases: “Stone” [MeSH], “Urolithiasis” [MeSH], “Nephrolithiasis” [MeSH] and “Calculi”
[MeSH]. Other key words for searching references were selected by each committee.
Other sources of information included: (i) JUA clinical guidelines for urolithiasis; (ii) EAU
Guidelines on Urolithiasis 2017, published by the EAU; (iii) Medical Management of Kidney
Stones: AUA Guidelines, published by the AUA; and (iv) Surgical Management or Stones:
AUA/Endourological Society Guidelines.
LE and GR
The LE and GR for each treatment were made based on the following strategy. The rec-
ommendations for treatment were based on a non-structured literature search, which has
been previously published, and labeled with a LE score according to a classification sys-
tem modified from the Oxford Centre for Evidence-based Medicine Levels of Evidence,
ranging from LE:1 (highest evidence level) to LE:5 (case study or expert opinion;
Table S1).1
Clinical questions and answers
Etiology
CQ 1. Is the prevalence of urinary stone disease increasing?
• The prevalence and incidence of urinary stone disease have increased in many countries in
recent years (LE:2, GR:A).
• There is growing evidence of an increasing incidence of stones in the USA (LE:2).
• The increase in the prevalence is less marked, or stable, in Europe (LE:3).
• An upward trend in urinary stone disease has been noted in Asia (LE:3).
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Table 1 Treatment approaches of different stone cases among different UAA representatives
47-year-old man, left
partial staghorn stone
(40 mm)
65-year-old man, left renal
pelvic stone (18 mm)
75-year-old woman, right
lower calyx stone (10 mm)
50-year-old women, right
mid-ureter stone (13 mm)
with moderate
hydronephrosis
8-year-old boy, right
renal pelvic stone
(8 mm)
Cambodia 1: Pyelo-nephrolithotomy
2: PCNL (+stenting)
1: Pyelolithotomy
(+stenting)
1: PCNL 1: URS
(+pre-stenting)
2: Ureterolithotomy
(+stenting)
1: Pyelolithotomy
(+stenting)
China 1: PCNL 1: RIRS or mini-PCNL
(HU >500)
2: SWL (HU <500)
1: Observation
2: RIRS
3: Micro to mini-PCNL
or
1: Ultra-mini-PCNL
1: URS
2: Antegrade URS
1: SWL
2: RIRS (+pre-stenting)
or
1: Ultra-mini-PCNL
Hong Kong 1: PCNL 1: PCNL 2: SWL 1: URS 1: SWL
India 1: PCNL
2: Robotic/laparoscopic
pyelolithotomy
3: Pyelolithotomy/extended
pyelolithotomy
1: PCNL (>1000 HU)
2: SWL (<1000 HU)
3: RIRS
1: SWL (favorable anatomy
and stone density)
2: RIRS
3: Mini-PCNL
1: URS
2: Laparoscopic
ureterolithotomy
1: SWL
2: Micro-PCNL
3: RIRS
Indonesia 1: Standard/mini-PCNL
2: RIRS
3: Pyelolithotomy
1: Standard/mini-PCNL
2: RIRS
3: SWL
4: Pyelolithotomy
1: SWL (infundibulum is wide
and angle of calyx >30)
2: RIRS
3: Standard/mini-PCNL
1: URS
2: Ureterolithotomy
1: SWL
2: RIRS
3: Mini-PCNL
Iran 1: PCNL
2: Multitract mini-PCNL
1: SWL
2: RIRS or mini-PCNL
1: SWL
2: RIRS or mini-PCNL
1: URS
2: Laparoscopic
ureterolithotomy
1: SWL
Japan 1: ECIRS by mini-PCNL 1: RIRS
2: Mini-PCNL (+RIRS)
1: SWL
2: RIRS
3: Observation
(depends on infundibular
length, width)
1: URS
(+pre-stenting or
nephrostomy tube
placement)
2: SWL
(+pre-stenting)
1: SWL
2: RIRS
(+pre-stenting)
Korea 1: PCNL (prone > supine)
2: ECIRS
1: RIRS
2: Mini-PCNL
3: PCNL
1: Observation
2: URS
3: SWL (if stone is not so
hard)
1: URS
(+pre-stenting or
nephrostomy tube
placement)
2: Antegrade URS
3: Laparoscopic
ureterolithotomy
1: RIRS
2: SWL
3: Mini-PCNL
Kuwait 1: PCNL
2: Staged RIRS
1: RIRS (+pre-stenting)
2: Mini-PCNL (+stenting)
1: RIRS (+pre-stenting)
2: SWL
1: URS 1: SWL
2: RIRS
Malaysia 1: PCNL 1: PCNL
2: RIRS (+pre-stenting)
1: Observation
(asymptomatic)
2: RIRS
3: SWL
4: Mini-PCNL with JJ stent
1: URS 1: SWL
2: Mini-PCNL
Nepal 1: PCNL 1: RIRS (HU <1100) or PCNL
(HU >1100)
(asymptomatic)
1: Observation
(symptomatic)
2: RIRS
1: URS 1: SWL
Singapore 1: PCNL 1: RIRS
2: SWL
1: SWL or RIRS (depends on
patient’s preference)
1: URS 1: SWL
Taiwan 1: PCNL
2: ECIRS
1: SWL
2: RIRS
3: Mini-PCNL
(HU >500 + severe
hydro)
1: RIRS 1: URS 1: SWL
2: Mini-PCNL
Thailand 1: PCNL 1: SWL or RIRS 1: SWL or RIRS 1: URS
(+pre-stenting)
1: SWL
Turkey 1: PCNL
2: ECIRS
1: RIRS (+stenting)
2: SWL (HU < 500)
1: Ultra-mini-PCNL 1: URS
2: Laparoscopic
ureterolithotomy
1: SWL
2: RIRS
Countries are indicated in alphabetical order. Numbers in each column indicate the preference order of treatment options.
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Commentary
Urinary stone disease is a highly prevalent disease worldwide,
with rates ranging from 7–13% in North America, 5–9% in
Europe and 1–5% in Asia; however, there is significant varia-
tion in rates based on geography, climate, diet, fluid intake,
genetics, sex, occupation and age.2–14 It is difficult to evalu-
ate the precise prevalence and incidence worldwide, because
there are differences in assessment methods across countries.
It should be noted that nationwide comparative studies are
rare in developing countries.15
CQ 2. How can stones be classified?
Stones can be categorized by etiology, chemical/mineral
names, size and location (LE:3, GR:A).
The most common stone type is calcium oxalate, and some
Asian countries have a higher percentage of this chemical
composition compared to other parts of the world (LE:3,
GR:A).
Stone composition is often associated with metabolic and/
or genetic abnormalities (LE:3, GR:B).
Commentary
Etiopathogenetic categorization of stones can include the fol-
lowing: non-infection stones, infectious causes, genetic-based
stones or drug-induced stones (LE:4).16
Stone composition is the basis for further diagnostic and
management decisions. Calcium phosphate stone composition
is more likely to be associated with certain medical condi-
tions or medications, such as renal tubular acidosis type 1,
primary hyperparathyroidism, medullary sponge kidney and
the use of carbonic anhydrase inhibitors (LE:3).17,18
Table 2 lists the clinically most relevant substances and
their mineral components. Some unique trends, including cal-
cium oxalate and cystine stones, have been reported from
each country throughout Asia (LE:4).19–24
CQ 3. What is the role of lifestyle in urinary stone disease?
• Metabolic syndrome is associated with stone formation
(LE:4, GR:B).
• Fluid intake volume has been shown to be inversely
related to urolithiasis (LE:1, GR:A).
• Soft drink consumption should be discouraged to reduce
new stone formation (LE:2, GR:B).
Commentary
Increased bodyweight and obesity have been shown to
increase the risk of urinary stone formation.25 A recent study
in Taiwanese men showed there was a significant correlation
between metabolic syndrome and nephrolithiasis.26 Visceral
fat was shown to be predictive of stone composition in a
Korean population.27 A higher fluid intake volume was asso-
ciated with reduced stone formation rates. Higher water
intake resulted in a reduced rate of stone recurrence in
patients with a previous episode of calcium stones.28–31 In
addition, soft drink and ascorbic acid were shown to increase
the risk of stone formation.29,30
CQ 4. What is the role of metabolic components in uri-
nary stone disease?
• Calcium intake should not be restricted, as there is an
inverse relationship between dietary calcium and stone
formation (LE:4, GR:A).
• High sodium intake is associated with an increased risk of
stone formation (LE:4, GR:A).
• Increased dietary ascorbic acid intake is associated with
hyperoxaluria (LE:3, GR:A).
• A low animal protein diet should be encouraged to reduce
the risk of stone formation (LE:2, GR:B).
• Dietary fiber content should be increased, and oxalate
content should be restricted in recurrent calcium oxalate
stone-forming cases (LE:4, GR:B).
Commentary
The Nurses’ Health Study in the USA found that the relative
risk of stone formation in women in the highest quintile of cal-
cium intake was 0.65 compared with those in the lowest quin-
tile.33 In a single randomized prospective study, hyperoxaluria
was shown to be significantly associated with dietary ascorbic
acid intake and inversely associated with calcium intake.32 A
low animal fat diet was reported to reduce stone recurrence
rates.34 Recent East Asian studies reported a decreased inci-
dence of calcium-containing stones and increased incidence of
uric acid stones in Korea,35 and a decreased incidence of uric
acid stones in Japan,11 during a 20-year observation period.
CQ 5. What is the role of genetic factors in urinary stone
disease?
• Genetic factors are highly associated with both the patho-
genesis and clinical outcomes of urinary stone disease.
Clinicians should consider patients’ genetic background,
including family history (LE:3, GR:A).
• Positive family history of urinary stone disease is associ-
ated with earlier disease onset and a higher risk of recur-
rence (LE:3, GR:B).
Table 2 List of variety of stone components
Chemical name Mineral name Chemical formula
Calcium oxalate monohydrate Whewellite CaC2O4H2O
Calcium oxalate dehydrate Wheddelite CaC2O42H2O
Basic calcium phosphate Apatite Ca10(PO4)6(OH)2
Calcium hydroxyl phosphate Carbonite
apatite
Ca5(PO3)3(OH)
b-Tricalcium phosphate Whitlockite Ca3(PO4)2
Carbonate apatite phosphate Dahllite Ca5(PO4)3OH
Calcium hydrogen phosphate Brushite PO42H2O
Calcium carbonate Aragonite CaCO3
Octacalcium phosphate Ca8H2(PO4)65H2O
Uric acid Uricite C5H4N4O3
Uric acid dehydrate Uricite C5H4O32H2O
Ammonium urate NH4C5H3N4O3
Sodium acid urate monohydrate NaC5H3N4O3H2O
Magnesium ammonium phosphate Struvite MgNH4PO46H2O
Magnesium acid phosphate trihydrate Newberyite MgHPO43H2O
Magnesium ammonium phosphate
monohydrate
Dittmarite MgNH4(PO4)1H2O
Cystine [SCH2CH(NH2)
COOH]2
Xanthine C5H4N4O2
2,8-Dihydroxyadenine C5H5N5O2
Drug stones (magnesium trisilicate;
ciprofloxacin; sulfa medications;
triamterene; ephedrine, melamine;
and indinavir)
Foreign body calculi
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• The association of gene mutations with disease develop-
ment has been reported for both rare inherited disorders
causing urolithiasis, as represented by cystine stones, and
idiopathic calcium stones (LE:3).
Commentary
Patients with urinary stone disease have a higher prevalence
of positive family history of the disease, which has been
reported to be between 30–50%.36–40 A family history of
urolithiasis increases the relative risk of stone disease by
2.57-fold in men.41 In addition, the concordance rate of the
disease in monozygotic twins is higher compared with dizy-
gotic twins (32.4 vs 17.3%; LE:3).42
Inherited metabolic disorders are often associated with
pediatric urolithiasis cases.43 Adenine phosphoribosyltrans-
ferase deficiency,44 cystinuria,45–47 xanthinuria,48 Dent dis-
ease,49,50 familial hypomagnesemia with hypercalciuria and
nephrocalcinosis,51,52 and primary hyperoxaluria53–55 cause
urinary hypersaturation of insoluble mineral salts, which can
inevitably increase the risk of kidney stone formation (LE:4).
In addition, a large number of reports in the literature have
focused on the association of gene single-nucleotide polymor-
phism/mutations with idiopathic calcium stone development
(LE:3).56
CQ 6. What is the role of regional or ethnic differences in
urinary stone disease?
• There is a clear geographic variation in stone incidence
worldwide (LE:3).
• The “stone belt” (areas where stones are frequent)
includes South-East Asia and West Asia (LE:2).
• Ethnic differences in the incidence of stone disease have
been observed (LE:3).
Commentary
The prevalence of urinary stone disease varies widely in different
regions of the world, and depends greatly on the geographic
area, racial distribution, socioeconomic status and dietary habits.
The geographic distribution of stone disease tends to roughly fol-
low that of environmental risk factors. Comparison of the accu-
rate prevalence of the disease is difficult because of the
differences in the evaluation methodology used.57
Racial differences in the incidence of stone disease have
also been observed.58 According to the NHANES dataset,
Hispanic (OR 0.60, P < 0.001) and black non-Hispanic peo-
ple (OR 0.37, P < 0.001) were significantly less likely to
report a history of stone disease compared with white non-
Hispanic people.59 A Canadian study reported that the rela-
tive risk of calcium nephrolithiasis was higher in individuals
of Arabic, West Indian and Asian descent, but lower in those
of East Asian descent than in those of European and Latin
American descent.60
CQ 7. What is the role of seasonal variation in urinary
stone disease?
• Seasonal variations are related to urinary calculi pain
attacks (LE:3).
• It has been suggested that there is an association between
the rise of the ambient temperature and the occurrence of
urolithiasis (LE:3).
• Seasonal variation in stone disease is likely related to tem-
perature by way of fluid losses from perspiration and by
sunlight-induced increases in vitamin D (LE:2).
Commentary
A close relationship between seasons and the incidence
of ureterolithiasis has been shown in various geographical
areas.61–67 Seasonal trends in monthly urinary stone attack rates
exist, with the incidence peaking in the summer, which is likely
related to the high temperature that leads to fluid losses due to
perspiration,68,69 and perhaps by sunlight-induced increases in
the synthesis of 1,25-dihydroxyvitamin D3 (vitamin D).
65,70 The
tendency for increasing incidence of renal colic in parallel with
the rise in ambient temperature has been well documented in
many countries.65,71 Conversely, other studies have shown that
the prevalence of urolithiasis is not related to season in Northern
Europe andWestern Australia, where the climate is stable.72–74
Diagnosis
CQ 8. What basic clinical work-up is necessary for the
diagnosis of urinary stone disease?
• Urine routine and microscopic investigations (red blood
and white blood cell counts, nitrites, urinary pH and cul-
ture, and sensitivity tests (LE:3, GR:B).
• Blood samples for total and differential counts, serum
urea, creatinine, Na and K are investigated in first-time
stone-former patients (LE:3, GR:B).
• If the patient is a recurrent stone former, then stone analy-
sis, serum (ionized) calcium, phosphorus, uric acid, mag-
nesium, as well as urinary calcium, phosphate, uric acid,
magnesium, citrates and cystine levels are investigated at
least once (LE:3, GR:B).
Commentary
If an intervention is planned, then PT, INR and blood group
testing should be carried out. All retrieved fragments or col-
lected stone material in voided urine should be examined by
X-ray diffraction or infrared spectroscopy methods. Stone
analysis should be carried out in recurrent stone formers dur-
ing each stone episode, even if the initial stone composition
is known, as changes in stone content have been reported in
recurrent stone formers.75–79
CQ 9. What is the recommended imaging modality for
the diagnosis of stone disease?
• Plain radiography is not sensitive and specific enough for
the diagnosis of stone (LE:4, GR:B).
• US is the recommended choice of diagnosis for most
renal stones and ureteric stones, particularly in children
(LE:4, GR:B).
• NCCT has the best sensitivity and specificity for the
detection of renal stones, and would be superior to US, in
particular for ureteric stones. However, risks of radiation
exposure should be considered (LE:4, GR:B).
• If possible, a low-dose NCCT protocol should be used for
patients with BMI <30 kg/m2, to minimize radiation risk
to patients (LE:4, GR:B).
Commentary
The accuracy of KUB for the diagnosis of urinary stones is
low, approximately 80–90% of stones are radiopaque, in partic-
ular during diagnostic settings (LE:4, GR:B).80,81
US has the advantage of being radiation-free, contrast-free
and readily available; however, the sensitivity/specificity for
diagnosing ureteric stones is low (LE:4, GR:B).80
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NCCT has high sensitivity and specificity for the detection
of both renal and ureteric stones (LE:4, GR:B).82,83 As radia-
tion exposure is a main concern, low-dose NCCT (with doses
<4 mSv) is recommended for the detection of ureteric stones
in patients with BMI <30 kg/m2.82 A study funded by the
Agency for Healthcare Research and Quality suggested the
use of US during the initial assessment of acute loin/abdomi-
nal pain suggestive of renal calculi, avoiding carrying out a
CT scan in some patients and hence resulting in less overall
radiation exposure than NCCT for all patients (LE:2, GR:A).84
CQ 10. Is an interview necessary for the diagnosis of
stone disease?
• Medical history is very important to diagnose stone dis-
ease. Physicians should ask detailed questions regarding
symptoms, including pain, nausea/vomiting, urine color,
discomfort on urination and previous stone episodes
(LE:1, GR:A).
• Obtaining information on habitual behavior regarding diet
and physical activity, family history, age of onset, and
previous stone episodes are also helpful to predict the risk
and recurrence of stones (LE:1, GR:A).
Commentary
Although 70% of patients have asymptomatic stones on US,
hematuria, flank/abdominal pains, prior stone episodes, nausea
and vomiting are common signs to suspect stone existence
(LE:1, GR:A).85,86 In addition, habitual behavior, including a
larger amount of diet and alcohol consumption, positive fam-
ily history, and less physical activity, is associated with the
risk for urinary stone disease (LE:3, GR:A).30,37,87–90 Positive
family history, younger age at onset and having two or more
previous stone episodes increase the prevalence of stone
recurrence (LE:1, GR:A).37,90–92
CQ 11. How should we diagnose urinary stones in specific
situations, such as in children and pregnant patients?
• In pregnant women, use US as a first-line imaging modal-
ity and MRI as a second-line approach (LE:2, GR:B).
• In pregnant women, reserve low-dose CT as a last-line
option (LE:2, GR:B).
• In children, US is a first-line imaging modality, and low-
dose CT is an alternative option if US cannot exclude uri-
nary calculi (LE:2, GR:B).
Commentary
For the diagnosis of urinary stones in pregnant patients, major
concerns are the effects of radiation exposure.93,94 Table 3
shows the radiation doses absorbed by a fetus after common
imaging modalities.91 The physician has to justify the need
for any investigation resulting in an absorbed dose to the
fetus of >0.5 mGy.93
US is the initial imaging modality for pregnant patients
suspected of renal colic;93,94 however, it has inherent disad-
vantages, such as operator dependency and the difficulty in
differentiation between physiological hydronephrosis of preg-
nancy and acute ureteral obstruction.95 Transvaginal US has
also been shown to improve sensitivity in the diagnosis of
distal ureteral stones.96 MRI is used as a second-line proce-
dure, to differentiate physiological from obstructive
hydronephrosis during pregnancy.93,94,97
Low-dose CT for the detection of urinary stones during
pregnancy has been associated with a higher positive
predictive value (95.8%) compared with MRI (80%) and US
(77%).98 Cumulative and long-term effects of radiation expo-
sure are again the major concerns for children; therefore, US
is the initial imaging modality for children suspected of renal
colic.99 US has 70% sensitivity and 100% specificity for the
detection of urinary stones in patients aged <18 years.100
CQ 12. What type of imaging work-up is necessary before
surgery?
• Use of nomograms of NCCT results can predict the stone
clearance rate, and therefore might guide optimal treat-
ment options (LE:2, GR:B).
• CT scan is also useful for clinicians in the preoperative
planning of PCNL by allowing the best and safest access
for stone clearance (LE:4, GR:B).
Commentary
For SWL, factors affecting the SFR include stone density
and skin-to-stone distance values (LE:4, GR:B).101 The stone
density can be measured using HU. Clinical algorithms for
the prediction of upper ureteric stone and renal stones, such
as the Triple D scoring system, have been developed to
define the most appropriate cases for SWL application (LE:4,
GR:B).102,103 For PCNL, Okunov et al. developed a novel sur-
gical classification system for kidney calculi, namely
S.T.O.N.E. (LE:4, GR:B).104 A nomogram was also developed
by the CROES PCNL Study Group in 2013 to predict the SFR
after PCNL, which showed an area under curve of 0.76 (LE:4,
GR:B).105 In Asia, the Modified S-ReSC Score was developed,
which assigned a score of 1–9 based on the number of sites
involved in the renal collecting system (LE:4, GR:B).106,107
The use of NCCT can provide most information required for an
appropriate and successful intervention. However, the use of
contrast-enhanced CT is sometimes required (LE:4, GR:C1).108
CQ 13. How can we determine renal function of each kid-
ney?
• Differential function of the kidneys can be attained by a
radionuclide renal scan (LE:3, GR:B).
• A more invasive investigation of differential function
includes determining the creatinine clearance of urine
obtained during percutaneous nephrostomy with or with-
out self-void urine (LE:5, GR:C).
• Use of US or NCCT for the assessment of cortical thick-
ness or cortical volume of the kidneys for the prediction
of differential kidney function has also been described
(LE:4, GR:C).
Commentary
The least invasive method for determining differential func-
tion is the use of radionuclide renal scan.109 However, in
Table 3 Radiation absorbed doses to the fetus for common imaging
modalities
Fetal dose (mGy)
Modality Mean Maximum
Ultrasound None
MRI (<1.5 Tesla) None
KUB radiography 1.4 4.2
IVU 1.7 10
CT 8.0 49
© 2019 The Japanese Urological Association 693
UAA clinical guideline for stone disease
patients with ureteral stones causing hydronephrosis, there is
a concern that the estimated differential function by conven-
tional nuclear scan might not be accurate and requires conju-
gate views for accurate evaluation (LE:4, GR:B).110
Alternatively, more invasive methods include the use of crea-
tinine clearance from urine collected from percutaneous
nephrostomy, compared with urine collected from contralat-
eral percutaneous nephrostomy or self-voided urine (LE:5,
GR:C). Carrying out cortical thickness or parenchymal volu-
metric measurement by using US or NCCT could help pro-
vide a reasonable prediction of the differential creatinine
clearance in obstructed kidneys (LE:4, GR:C1).111
Metabolic evaluation
CQ 14. Is metabolic evaluation necessary for stone disease
patients?
• Basic evaluation with serum chemistry and urinary analy-
sis is recommended for all patients presenting with stones
(LE:4, GR:B).
• Metabolic evaluation including 24-h urine collection is
recommended for patients at high risk of stone recurrence
or formation (LE:4, GR:B).
Commentary
Metabolic evaluation of stone disease can reveal abnormali-
ties, which are amenable to medical treatment. In recurrent
stone formers, metabolic evaluation, including serum mineral,
parathormone and 24-h urine chemistry, showed significant
serum and urinary abnormalities in contrast to first-time stone
formers in an observational study.112 Medical treatment of
stone disease has been shown to reduce the risk of stone
recurrence in a meta-analysis of RCTs (LE:4, GR:B).113
CQ 15. Is it necessary to identify stone components?
• Stone analysis should be carried out for all first-time stone
formers (LE:4, GR:C).
• Stone analysis should be repeated at every attack or inter-
vention for patients with early stone recurrence after inter-
vention, or late recurrence after a stone-free period (LE:3,
GR:C).
Commentary
Stone analysis is an important part of the complete evaluation
for a patient with stone disease. For example, calcium oxalate
monohydrate stones can be associated with intermittent
hyperoxaluria from high oxalate intake, decreased diuresis or
inherited diseases, such as primary hyperoxaluria.114 For
patients with recurrent stone disease, the stone composition
might change over time, which can impact on the efficacy of
preventive treatments.78
CQ 16. Are biochemical tests by 24-h urine necessary?
And when?
• Twenty-four hour urine tests are recommended for patients
deemed at high risk of stone formation (LE:3, GR:B).
• Two separate 24-h collections should be carried out for a
complete biochemical work-up (LE:4, GR:B).
• Collection of samples should be carried out for patients
who have been stone-free for at least 20 days (LE:4,
GR:B).
• Repeat evaluation is recommended for patients on phar-
macological treatment for recurrence (LE:4, GR:B).
Commentary
The list of characteristics that classify a patient as a high-risk
stone former is extensive.115 High-risk stone formers should
be counseled for 24-h urine evaluation including pH, miner-
als, oxalate, citrate and amino acids, as the results can guide
medical prevention.116,117 Spot urine tests have been used as
an alternative for patients who are not willing or unable to
carry out 24-h urine collection.118 There is limited evidence
for the timing of repeat urine collections, but most consen-
suses recommend a repeat collection at 8–12 weeks after
commencement of pharmacological therapy. Repeat urine
analysis allows titration of drug doses as necessary.119
Medical management
CQ 17. What is the recommended treatment for ureter
stone pain management?
• Use NSAIDs to control the colic pain (LE:2, GR:A).
• Use alpha1-blockers (e.g. tamsulosin) as a treatment
option for distal ureteral stones of >5 mm in size (LE:1,
GR:A).
Commentary
NSAIDs are effective for patients with acute stone colic, and
have better analgesic efficacy than opioids (LE:3).120,121
Intramuscular NSAIDs offer the most effective sustained
analgesia for renal colic, and seem to have fewer side-effects
(LE:2).122 For patients with ureteral stones that are expected
to pass spontaneously, NSAID tablets or suppositories (e.g.
diclofenac sodium, 100–150 mg/day, 3–10 days) might help
reduce inflammation and the risk of recurrent pain
(LE:1).123,124
MET refers to the administration of drugs (e.g. tamsulosin
or nifedipine) that expedite the passage of the stone without
the need for surgical intervention.125,126 Meta-analysis studies
have clearly shown that patients with ureteral stones treated
with alpha1-blockers can reduce the number of pain episodes,
the need for analgesic medication (diclofenac) and hospital-
ization (LE:1).127 Administration of tamsulosin and nifedipine
in MET was determined to be safe and effective for distal
ureteric stones with renal colic; tamsulosin was significantly
better than nifedipine in relieving renal colic and facilitating
ureteric stone expulsion (LE:1).128,129
CQ 18. What promotes spontaneous passage of urinary
stone?
• Small stones (ureteral stones of <10 mm in size) are
highly likely to pass spontaneously (LE:2, GR:A).
• Stone location at the lower ureter with no obstruction
(LE:4, GR:B).
• Anti-inflammatory drugs. Inflammatory changes in the
ureter provoke a reduction in the rate of spontaneous pas-
sage of urinary stones; therefore, anti-inflammatory drugs,
such as NSAIDs and steroids, are generally considered to
increase spontaneous passage of urinary stone rates (LE:4,
GR:B).
• Alpha1-blockers have been recommended for muscle
relaxation of the lower ureter and to promote spontaneous
ureter stone passage (LE:1, GR:A).
• Use of external physical vibration lithecbole is a treatment
option (LE:1, GR:B).
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Commentary
Tamsulosin significantly facilitated the passage of distal uret-
eral stones in patients with well-controlled pain, no infec-
tions, abnormal anatomy, renal insufficiency or high-grade
obstruction (LE:1).129 No improvement in stone passage rates
was observed in patients with ≤5-mm distal ureteral stones
treated with tamsulosin (LE:1).129 While one RCT does not
recommend the use of tamsulosin for symptomatic stones
<9 mm,130 a similar result was shown by another RCT
trial.131–133 However, several well-designed, randomized,
double-blind, placebo-controlled studies have recently pro-
duced contradictory results, showing no overall benefit of
MET.131–135 Only the subgroup analysis for stones of 5–
10 mm showed a higher passage rate in the tamsulosin group,
by relaxing ureteral smooth muscle and decreasing the uret-
eral wall tone (LE:1).136,137
Low NLR (<2.3) might predict spontaneous stone passage
in patients with ureter stones <10 mm in size, suggesting that
ureteral inflammation plays an important role in stone passage
(LE:4).131 External physical vibration lithecbole was found to
be efficacious in assisting the discharge of lower pole renal
stone fragments, and can be used as an adjunctive method of
minimally invasive stone treatment (LE:1–3).138–142
CQ 19. What is the role of medical chemolysis in uric acid
stone?
• Uric acid stones can be dissolved by medical chemolysis
using oral alkaline citrate or sodium bicarbonate through
alkalinization of urine (LE:2, GR:A).
Commentary
Urinary concentration of uric acid depends on urine pH, urine
volume and excretion of uric acid. Urinary pH is the most
important factor in uric acid solubility.143 Oral alkaline citrate
or sodium bicarbonate is used for chemolysis through alkalin-
ization of the urine.144 Although the efficiency of chemolysis
is directly proportional to higher pH, the pH should be
adjusted in the range of 7.0–7.2 to prevent formation of cal-
cium phosphate calculus.
CQ 20. What medical treatment is appropriate for
pyelonephritis accompanying urinary stone?
• Active antibiotic treatment and timely drainage of kidney
if necessary (LE:1, GR:A).
• Percutaneous nephrostomy and ureteral catheter insertion
(LE:2, GR:A).
• Nephrectomy is advocated as the treatment of choice for a
kidney that has lost most of its function and the contralat-
eral kidney is normal (LE:1, GR:A).
• Remove and cure of the lithiasis after the treatment of
UTI, which is the main etiological factor in this pathology
(LE:1, GR:A).
Commentary
The treatment approaches of pyelonephrosis accompanying uri-
nary stone should be individualized based on the age, general
condition of the patient and patient compliance (LE:1).145 Ret-
rograde ureteral catheterization is appropriate for drainage of
hydronephrosis (LE:2).146 In addition, percutaneous nephros-
tomy provides a means of draining off pus and determining pos-
sible residual renal function.146 If carried out properly,
percutaneous drainage is a fast, reliable, and quickly effective
therapeutic method in one session (LE:1).147 The combination
of medical management and percutaneous drainage decreased
the mortality rate of obstructive emphysematous pyelonephritis
to 13.5%, compared with 50% with medical management
alone.148 Nephrectomy is advocated as a treatment option in the
case of a damaged kidney, which seems difficult to be preserved
by conservative and endourological treatment, with a normally
functioning contralateral kidney (LE:3, LE:1).149,150 The best
treatment consists of the removal and cure of the lithiasis, which
is the main etiological factor in this pathology (LE:2).146
Surgical management
CQ 21. When can SWL be the first option for patients
with renal stones?
• While SWL is an option for most renal stones, it should
not be applied to patients who are contraindicated for
SWL or have abnormal renal anatomy, such as caliceal
diverticulum and so on (LE:5, GR:A).
• For renal stones <20 mm, SWL is a recommended first-
line treatment for patients (LE:3, GR:A).
• For stones >20 mm or for renal stones presenting less
favorable factors, such as high mean stone density or
located in calices with poor anatomy, the treatment out-
come will be less favorable. Therefore, the pros and cons
of each treatment modality should be discussed in detail
with the patient before a joint decision on treatment plan
can then be taken (LE:5, GR:B).
• SWL is highly effective in pediatric cases due to its non-
invasive nature and higher SFRs compared with adults
(LE:2, GR:B).
Commentary
SWL might be considered as the first treatment option for the
index patient who has no contraindication for SWL, with
stones sized <20 mm in general151 or <10 mm for lower cal-
iceal stones with favorable anatomy and composition (non-
cystine, non-calcium monohydrate stone or stone CT
HU <1000; LE:4).100,101,152 For a patient with contraindication
for SWL, abnormal body habitat, hard stone or unfavorable
renal anatomy, other treatment options should be considered.
CQ 22. What are the complications of SWL?
• In general, the incidence of complications of SWL is low,
and the majority are clinically not severe (LE:4, GR:B).
• The most severe complication, symptomatic hematoma, is
detected in <1% of cases (LE:4, GR:B).
• There is no evidence suggesting SWL has long-term side-
effects for patients (LE:4, GR:B).
Commentary
The incidence of complications after SWL is low and most
are mild (LE:4, GR:B).153–155 Complications of SWL can be
divided into three types: intraprocedure,150 early complica-
tions156,157 and long-term complications (Table 4).158,159
Major contraindications are pregnancy, uncontrolled UTI and/
or coagulation disorders, and the presence of an aortic or
renal aneurysm.160
CQ 23. What are the complications of lithotripsy by
URS?
• The overall complication rate after URS is 9–25%. Most
complications are minor and do not require intervention
(LE:1, GR:A).
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• The following complications are the most relevant
(Table 5): sepsis; ureteral stricture; ureteral injury; and
UTI.
• Serious complications, including death and loss of kidney,
were sufficiently rare that data were not available to esti-
mate their rates of occurrence (LE:1, GR:A).
Commentary
The overall complication rate after URS is 9–25%.161 The
most relevant intraoperative and postoperative complications
are sepsis, ureteral stricture, ureteral injury and UTI. Ureteral
avulsion and strictures are rare (<1%). Previous perforations
are the most important risk factors for complications (LE:1,
GR:A).
CQ 24. What are the complications of PCNL?
• The complication rate of PCNL was reported to range
from 10% to 20%, and most of the complications were
not severe (LE:1, GR:A).
• The most common postoperative complications associated
with PCNL are fever and bleeding, and urinary leakage
(LE:1, GR:B).
• The complication rates of standard PCNL and minimally
invasive PCNL were reported to be 15.9% and 12.8%,
respectively. Minimally invasive PCNL is at least as effi-
cacious and safe as standard PCNL (LE:1, GR:A).
Commentary
The complication rate of standard PCNL was reported to be
15.9%, whereas that of minimally invasive PCNL was
reported to be 12.8% (LE:1).162,163 The complication rate of
PCNL improved from 21.3% between 1997 and 2005 to
10.3% between 2006 and 2014 (LE:3).164 The most common
postoperative complications associated with PCNL are fever
and bleeding, urinary leakage, and problems due to residual
stones (LE:1; Table 6).165 Clavien 1, 2, 3, 4 and 5 complica-
tions were observed in 88.1%, 7%, 4.1%, 0.6% and 0.04% of
cases, respectively.165 One RCT has compared ECIRS with
minimally invasive PCNL, and showed that no significant
difference in perioperative complications including blood
transfusion was observed between the two groups
(P = 0.409; LE:2).166
CQ 25. What situation(s) require(s) open/laparoscopic/
robotic-assisted stone surgery?
• Although endoscopic management is a standard approach
for most stone removal surgery, open/laparoscopic/
robotic-assisted surgery might be alternatives in selected
situations, such as stones requiring complete removal
within a single session (infection stones) or stones with
urinary tract anatomical abnormalities requiring simultane-
ous reconstruction (LE:5, GR:C1).
Table 4 Common complications after SWL
Complications
EAU
guidelines
Sun and Zhang
(Chinese group)154
(LE:4)
Jagtap et al.
(Indian
group)155
(LE:4)
Intraprocedure
Dysrhythmia 11–59% – –
Early complications
Hematoma
(symptomatic)
<1% – 0.48%
Hematoma
(asymptomatic)
4–19% – –
Renal colic 2–4% 1.3–3.7% 1.02%
Steinstrasse 4–7% – 1.96%
Sepsis 1–2.7% 4.0–7.4% 2.05%
Long-term complications
Regrowth of residual
fragments
21–59% – –
Table 5 Common complications with URS compared with SWL
SWL URS
Groups/
patients
Median/
95% CI
Groups/
patients
Median/
95% CI
Distal ureter
Sepsis 6 3% 7 2%
2019 2–5% 1954 1–4%
Ureteral stricture 2 0% 16 1%
609 0–1% 1911 1–2%
Ureteral injury 1 1% 23 3%
45 0–5% 4529 3–4%
UTI 3 4% 3 4%
87 1–12% 458 2–7%
Mid ureter
Sepsis 2 5% 4 4%
398 0–20% 199 1–11%
Ureteral stricture 1 1% 7 4%
43 0–6% 326 2–7%
Ureteral injury 10 6%
514 3–8%
UTI 1 6% 1 2%
37 1–16% 63 0–7%
Proximal ureter
Sepsis 5 3% 8 4%
704 2–4% 360 2–6%
Ureteral stricture 2 2% 8 2%
124 0–8% 987 1–5%
Ureteral injury 2 2% 10 6%
124 0–8% 1005 3–9%
UTI 5 4% 2 4%
360 2–7% 224 1–8%
Table 6 Perioperative complications of percutaneous nephrolithotomy
Complication Frequency (%) Range
Fever 10.8 0–32.1
Transfusion 7 0–20
Thoracic complications 1.5 0–11.6
Sepsis 0.5 0.3–1.1
Embolization 0.4 0–1.5
Organ injury 0.4 0–1.7
Urinoma 0.2 0–1
Death 0.05 0–0.3
Total n = 11 929.
696 © 2019 The Japanese Urological Association
K TAGUCHI ET AL.
Commentary
For large stones or stones with complex configuration,
open/laparoscopic/robotic-assisted surgery might clear all
stone burden within a single session. Several reports
showed the simplicity of the procedure and excellent out-
comes resulting from laparoscopic pyelolithotomy with or
without concomitant pyeloplasty.167,168 Both the transperi-
toneal and retroperitoneal approach resulted in similar
SFRs.169 Laparoscopic management of symptomatic caliceal
diverticular stone is effective in diverticula with thin over-
lying renal parenchyma or anterior lesions inaccessible by
endourological techniques.170 Laparoscopic anatrophic
nephrolithotomy can be carried out selectively in large
staghorn stones requiring complete removal in a single sur-
gical session.171 Finally, laparoscopic ureterolithotomy
might be an alternative for impacted large proximal ureteral
stones.172
CQ 26. What urinary stones are eligible for ECIRS?
• Possible indications requiring combined approaches to the
kidney or ureter (LE:2, GR:B):
○ large and complex stones;
○ large renal and concomitant ureteral stones or strictures;
○ ipsilateral medium-to-large renal stones and contralat-
eral small renal stones;
○ diverticular stones with a difficult angle to the
infundibulum or a narrow infundibulum;
○ difficulty of angle to approach from the calyx of the percu-
taneous puncture to other calyces to avoid multiple tracts;
○ impacted UPJ stones with complete obstruction; and
ureteral strictures that require an antegrade incisional
procedure.
Commentary
The retrograde approach using a flexible ureteroscope has
shown good surgical outcomes. However, the antegrade
approach using a flexible ureteroscope or nephroscope can
increase the SFRs in cases of acute infundibulopelvic angle
or narrow infundibulum, musculoskeletal deformities, or
anatomical abnormalities (LE:2).166,173–175 ECIRS can be car-
ried out in either the supine or prone position. However,
there has been no randomized controlled study examining the
patients’ position (LE:4).173,176,177 ECIRS contains two dif-
ferent concepts of location (bidirectional) and time (simulta-
neous; Fig. 1).176,178 Selection of the combined bidirectional
or simultaneous bidirectional approach depends on the loca-
tion and size of the renal stones (Fig. 2).
CQ 27. What urinary stones are eligible for miniaturized
PCNL?
• Miniaturized PCNL can be recommended to treat med-
ium-sized renal stones with promising good surgical out-
comes with comparable SFRs and reduced risk of
morbidity (LE:1, GR:B).
Commentary
The acceptable criteria on stone burden of the miniaturized
PCNL has been medium-sized renal stones <3.0–3.5 cm, and
ultraminiperc or microperc might be suitable for stones
<1.5 cm.179–182 Miniaturized PCNL can be considered when
there are diverticular stones, and pediatric medium-sized stones
as well (LE:4).179,180,183 Miniaturized PCNL has shown com-
parable surgical outcomes to conventional PCNL in terms of
SFRs with lower probability of complications;184,185 however,
it seems to have longer operative times and higher intrarenal
pressure than conventional PCNL during surgery.186,187 The
surgical outcomes of miniaturized PCNL are promising, with
good SFRs, shorter hospital stay and reduced risk of morbid-
ity, such as bleeding, adjacent organ injury and so on
(LE:1).186 Miniaturized PCNL and RIRS have similar indica-
tions for medium-sized renal stones <3 cm;188 however, safety
concerns regarding the higher bleeding risk, larger hemoglobin
drop or longer hospital stay of miniaturized PCNL compared
with RIRS arose (LE:1).189,190
Bidirectional
bilateral approach
ECIRS
URS
1 4
Flex URS
Flex nephto
mPCNL
PCNL
Supine
Prone
2 3
Fig. 1 Development of stone surgery in the era of flexible ureteroscopy. Numbers 1–4 represent the turning point where a surgeon needs to select a surgical
option. (1) Rigid or semi-rigid ureteroscopic surgery was developed for flexible ureteroscopic surgery to remove renal stones. (2) The use of a miniaturized nephro-
scope became one of the good options for removal of large renal stones in conjunction with 30-Fr conventional percutaneous nephrolithotomy. (3) Percutaneous
nephrolithotomy in the supine position is increasingly used. (4) The bidirectional approach with a flexible ureteroscope for bilateral renal stones became more
common due to development of the procedure with device innovation. Furthermore, ECIRS using flexible ureteroscopes and percutaneous nephroscopes in a sin-
gle session is gaining increasing attention worldwide.
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CQ 28. What is the algorithm for treatment of adult
patients with symptomatic renal stones?
• Considering its low stone-free rate for stones >15 mm,
RIRS could be carried out for stones up to 20 mm in size
(LE:2, GR:B).
• Although there is limited evidence about the choice of
appropriate surgical approach for symptomatic renal
stones, mini-PCNL with 14–20-Fr tracts is accumulating
more evidence regarding the reliability and safety consid-
erations (LE:1, GR:B).
• However, ultramini-, micro-PCNL, or the ancillary use of
miniaturized nephroscopes and flexible ureteroreno- or
nephroscopes has shown limited evidence based on obser-
vational or retrospective studies (LE:4, GR:C1).
Commentary
The summarized flow chart for treatment algorithm is shown
in Figure 3.166,174–181,184,185,188,189,191–206
CQ 29. What is an algorithm for treatment of adult
patients with ureteral stones?
• Expectant management or MET might be considered for
non-obstructing ureteral stones without complications
(LE:1, GR:B).
• Once the surgery is indicated, URS or SWL are accept-
able (LE:2, GR:B).
Commentary
The summarized flow chart for treatment algorithm is shown
in Figure 4.135,207–214
CQ 30. How can we manage urinary stones in specific sit-
uations, such as children and pregnant women?
• In pregnant patients with uncomplicated urinary stones,
offer conservative management as a first-line therapy
(LE:4, GR:B).
• URS has emerged as a preferred treatment for pregnant
patients who failed conservative management (LE:2,
GR:B).
• Placement of a ureteral stent or a percutaneous nephros-
tomy tube is an alternative option, with frequent stent or
tube changes usually being necessary (LE:2, GR:C).
• In children with uncomplicated ureteral stones ≤10 mm,
offer conservative management as a first-line therapy
(LE:4, GR:B).
• Both SWL and URS are the treatments of choice for chil-
dren with ureteral stones who are unlikely to pass the
stones or who have failed conservative management
(LE:2, GR:B).
• All three surgical modalities (SWL, URS, PCNL) are
acceptable treatment options for children with renal stones
(LE:2, GR:B).
Commentary
The spontaneous stone passage rates for pregnant patients
ranges from 48% to 84%.91 NSAIDs are contraindicated in
pregnancy. Frequent small doses of morphine can be used
safely for severe pain, and acetaminophen for mild analge-
sia.93,94 The use of MET for pregnant patients as “off-
label” use remains debatable.94 When clinical indications
for intervention emerges, placement of a ureteral stent or
percutaneous nephrostomy tube is an effective
option;94,215,216 however, URS has been identified as a rea-
sonable alternative in these situations.217–219 SWL is an
absolute contraindication, and PCNL should be generally
avoided.93,94
An initial trial of conservative management should be
offered for children with uncomplicated ureteral stones,
because spontaneous stone passage is expected in a signifi-
cant proportion of children.99,220 SWL provides more effec-
tive disintegration of large stones, and rapid and
uncomplicated discharge of fragments compared with adult
patients.221 With the development of intracorporeal lithotripsy
devices and smaller-caliber instruments, indications for URS
and PCNL are similar to those for adult patients.222,223
CQ 31. How should asymptomatic small renal stone be
managed?
• Asymptomatic stones develop symptomatic events in
31.8–53.6% of patients within 5 years (LE:4).
• Clinicians can offer active surveillance for patients with
asymptomatic renal stones due to their low probability for
Ipsilateral bidirectional
(ECIRS)
Bilateral bidirectional
(ECIRS + contralateral)
Fig. 2 Combined approach to removing stones
simultaneously. Endoscopic intrarenal surgery can
be considered using multiple approaches with a
flexible scope in combination with a rigid
nephroscope to remove renal stones in an
ipsilateral kidney. Bilateral renal stones can be
removed in a single session in some cases.
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developing symptomatic events requiring interventions
(LE:2, GR:C).
• Asymptomatic renal stones should be treated in situations
of rapid growth and development of symptoms (LE:2,
GR:A).
Commentary
A prior retrospective cohort study showed that 31.8% of
asymptomatic stone patients developed symptomatic stone
events in 31.6 months of mean study follow up.224 Recent
cohort studies reported that the development of symptomatic
stone events were 53.6% for 31 months of mean follow up and
42% for 4.7 years of median follow up, respectively.225,226
Studies suggested that larger stone size, in particular volume,
and rapid increase in stone volume appeared to be predictive of
future stone events in patients with asymptomatic stones
(LE:4).227,228 Some RCTs reported that observation of asymp-
tomatic renal stone did not affect the patient’s follow up com-
pared with SWL or PCNL (LE:2).229,230 A patient decision-
based survey showed that 22.8% chose observation, which
revealed that the patients who had passed larger stones were
less likely to choose observation over surgery (LE:4).231
Recurrence prevention
CQ 32. Is hydration effective for stone prevention and
how much fluid intake should be recommended?
• Hydration is clinically useful for secondary stone preven-
tion by a urine dilutional effect. Urinary stone patients
should be advised to achieve a goal of 2–2.5 L of urine
daily (LE:2, GR:A).
Commentary
Increased fluid intake, which results in urine dilution, is a
widely accepted measure to reduce recurrent stone forma-
tion.232,233 An RCT has shown that stone formers who
were assigned to increase fluid intake to achieve a urine
volume ≥2 L/day had a significantly lower stone recur-
rence rate compared with controls (12% vs 27%,
P = 0.008).28 In general, adequate hydration with a goal
of at least 2–2.5 L of urine daily should be recommended.
A non-invasive fluid tracker, a combination of a fluid
tracking system and mobile health technology, has consid-
erable potential to help urinary stone patients achieve high
fluid intake.234
RIRS*
ECIRS
>3020-3015-2010-15<10
RIRS
SWL
ECIRS
Standard-PCNL
>3020-3015-2010-15<10
RIRS
Mini-PCNL
ECIRS
Standard-PCNL
>3020-3015-2010-15
RIRS
Ultramini-/Micro-PCNL
Mini-PCNL
ECIRS
Standard-PCNL
>3020-3015-2010-15<10
SWL
YES
NO
NO
YES
YES NO
(1)
(2)
(3)
(4)
Anatomical abnormalities?
(such as diverticular/horseshoe
kidney stones, etc)
With concomitant
ureteral stone?
With larger lower
pole burden** ?
Ultramini-/
Micro-PCNL
Ultramini-/
Micro-PCNL
Mini-PCNL
Standard-PCNL
Mini-
PCNL
Fig. 3 Flow chart for treatment of adult patients with symptomatic renal stones. The first step in considering surgical intervention for renal stones is to con-
firm any anatomical abnormalities. (1) Horseshoe kidneys with calyceal diverticula usually have narrow and long infundibula, making SWL ineffective; therefore,
either RIRS or PCNL should be considered, depending on the stone burden. In addition, miniaturized PCNL and ECIRS could be an option, depending on
anatomical features. (2) A concomitant ureteral stone is more appropriately managed with a retrograde approach, using RIRS or ECIRS. Antegrade lithotripsy
with mini- or standard-PCNL is also appropriate for a stone >20 mm. (3) Large lower pole stones measuring ≤20 mm should be treated with RIRS or miniatur-
ized PCNL, and lower pole stones >20 mm should be treated with standard PCNL or ECIRS. SWL is less effective due to potential postprocedure complica-
tions and limited evidence for efficacy. (4) Small, simple renal stones are treatable with SWL, RIRS or miniaturized PCNL. Stones >20 mm should be treated
using standard PCNL or ECIRS. *There are some limitations/exceptions regarding the anatomical difficulties in approaching the stone with a flexible uretero-
scope. **Cases predominantly having lower caliceal stones >10 mm.
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CQ 33. What are the components that affect the risk of
recurrence that are effective for prevention of stone dis-
ease?
• Stone type and disease severity determine recurrent risk,
including general factors, diseases associated with stone
formation, genetically-determined stone formation, drug-
induced stone formation, anatomical abnormalities associ-
ated with stone formation and environmental factors
(LE:2, GR:B).
• Normalization of dietary habits with adequate fluid intake
and a balanced diet, adequate physical activity, and main-
tenance of a normal BMI level are the main strategies for
preventing stone disease (LE:1, GR:A).
Commentary
Stone type and disease severity determine a low or high risk
of recurrence (Table 7).235–238
All stone formers, independent of their individual risk,
should follow the suggested preventive measures, whose
main focus is normalization of dietary habits and lifestyle
risks (Table 8).239–244 Stone formers at high risk require
specific prophylaxis for recurrence,245,246 which is usually
pharmacological treatment based on stone analysis
(Table 9).
CQ 34. What foods are effective for preventing the recur-
rence of calcium stones?
• A common-sense approach to diet should be taken; that
is, a mixed balanced diet with contributions from all food
groups, without any excesses. Fruit and vegetable intake
are encouraged; oxalate-rich products, vitamin C and ani-
mal protein should be restricted; and excessive intake of
calcium should be limited (LE:2, GR:B).
Commentary
The effect of fruit juices is mainly determined by the presence
of citrate, bicarbonate and pottassium.32,247–249 Potassium
increases both pH and citrate (LE:2, GR:B). Fruit and veg-
etable intake should be encouraged because of the beneficial
effects of fiber, although the role of the latter in preventing
stone recurrences is debatable (LE:1, GR:A).250–253 Excessive
intake of oxalate-rich products should be limited or avoided to
prevent high oxalate load, particularly in patients who have
high oxalate excretion (LE:3, GR:C).32 As its role as a risk fac-
tor in calcium oxalate stone formation remains controversial,254
avoiding excessive vitamin C intake seems wise for calcium
oxalate stone formers (LE:3, GR:C).255 Excessive consumption
of animal protein has several effects that favor stone formation,
including hypocitraturia, low urine pH, hyperoxaluria and
hyperuricosuria, and should be limited to 0.8–1.0 g/kg body-
weight (LE:1, GR:A).30,34 Calcium intake should not be
restricted unless there are strong reasons due to the inverse rela-
tionship between dietary calcium and stone formation (LE:1,
GR:A).33,251 Calcium supplements are not recommended
except in enteric hyperoxaluria (LE:1, GR:A).34 Calcium stone
formation can be reduced by restricting sodium and animal
protein (LE:1, GR:A).30,34,251,256
CQ 35. Does salt intake increase the risk of urinary stones?
• Clinicians should provide patients with calcium stones
suitable information about restriction of sodium intake
and the necessity of appropriate intake of dietary calcium
of 1000–1200 mg per day (LE:2, GR:C1).
Commentary
Dietary salt – sodium chloride – is linked to calcium excre-
tion in urine.257 An RCT showed that a lower salt diet with a
Observation
MET**
>105-10<5
YES
NO
(not require surgery)
Proximal
Distal
Observation
MET?**
>10<10
Proximal
Distal
SWL
Antegra-
de URS
SWL
URS
NO
Observation
Recurrence prevention 
YES*
URS
(1)
(2) (3)
Obstructing, symptomatic,
increased creatine? 
Pass out after a period of
conservative management
Fig. 4 Flow chart for treatment of adult patients with ureteral stones. Stone-related and patient factors should be considered when treating adults with ureteral
stones. (1) The first step is to verify whether the patient has an indication for active stone removal, including significant urinary obstruction, stone-related symp-
toms and progressive renal deterioration. (2) In the absence of an indication for active stone removal, close observation or MET should be offered. In general,
small ureteral stones have a high probability of spontaneous passage, especially when located in the distal ureter. MET can be appropriate for distal ureteral
stones >5 mm and proximal ureteral stones larger than 10 mm. (3) If active stone removal is clinically indicated, URS, using either a retrograde or antegrade
approach, and SWL are usually considered. Proximal ureteral stones >10 mm can be treated with URS more efficiently than with SWL. *These conditions might
require ureteral stent insertion or percutaneous nephrostomy tube placement before removal of stones. **A treating physician should consider early surgical inter-
vention in parallel during the trial of medical treatment.
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target of ≤100 mEq (2300 mg) could reduce calcium excre-
tion in urine for hypercalciuric stone formers (LE:2).34 Previ-
ous interventional studies have reported a linear association
between salt intake and urinary calcium excretion.258,259
Intake of high dietary salt diminishes the efficacy of reab-
sorption of sodium and water in renal proximal tubules,
which prevents calcium reabsorption.260,261 This hypercalci-
uric status might facilitate stone formation.262
CQ 36. Does animal protein intake increase the risk of
urinary stones?
• Animal protein lowers urinary pH and increases uric acid
in urine. Intake of excessive animal protein is one of the
risk factors for excessive uric acid excretion and calcium
stone formation (LE:1, GR:B).
Commentary
Previous clinical,34 epidemiological256,263 and metabolic264
studies have suggested that excessive consumption of animal
protein might induce stone formation (LE:4).256,264–266 For
patients with recurrent calcium oxalate stones, limited animal
protein intake of 0.8–1.0 g/kg/day reduces stone formation
(LE:1).30
CQ 37. Does thiazide prevent urinary stones?
• Clinicians might recommend thiazide medication with or
without potassium citrate to patients with high or rela-
tively high urinary calcium, as well as recurrent calcium
stone formers without definite evidence of metabolic
abnormalities (LE:1, GR:B).
Commentary
Thiazide reduces recurrent calcium stone formation by the
hypocalciuric effect with once-daily use of 50 mg
hydrochlorothiazide, 25 mg chlothalidone and 2.5 mg inda-
pamide (LE:1).34,267–271 Potassium citrate or potassium chlo-
ride might be necessary to prevent hypokalemic effects
induced by thiazide medication.
CQ 38. Does citric acid prevent urinary stones?
• Various citrus juices can be utilized to induce citraturia.
However, whether this approach can reduce calcium
stone recurrence is still under investigation (LE:4,
GR:C1).
Commentary
Administration of citrate has been shown to benefit hypocitra-
turic stone formers.272 Orange juice effectively induces citra-
turia due to its high concentration of potassium citrate.273
Lemonade and lime juice show increased urinary citrate in
some studies,274 but not in others.275 Grapefruit juice not
only increases urinary citrate, but also increases oxalate
excretion, so its protective effect is offset.276
CQ 39. Does magnesium prevent urinary stones?
• Magnesium inhibits calcium oxalate stone formation either
in vitro or in vivo, and several studies have shown its pro-
tective effects based on urinary parameters. Most clinical
trials utilizing magnesium in combination with other stone
inhibitors showed promising results. However, magnesium
as sole therapy is ineffective and is not recommended
(LE:4, GR:D).
Commentary
Urinary magnesium complexes with oxalate, which reduces
calcium oxalate supersaturation, inhibit the nucleation and
growth of calcium oxalate crystals.277,278 Furthermore, recent
data have shown that its inhibitory effect synergizes with
citrate and continues to be effective at an acidic pH environ-
ment.279 Magnesium supplement in calcium stone formers
Table 7 Examples for high-risk stone formers
General factors
Early onset of urolithiasis (especially children and teenagers)
Familial stone formation
Brushite-containing stones (CaHPO42H2O)
Uric acid- and urate-containing stones
Infection stones
Solitary kidney (the kidney itself does not particularly increase the risk
of stone formation, but prevention of stone recurrence is of more
importance)
Diseases associated with stone formation
Hyperparathyroidism
Metabolic syndrome
Nephrocalcinosis
Polycystic kidney disease
Gastrointestinal diseases (i.e. jejuno-ileal bypass, intestinal resection,
Crohn’s disease, malabsorption conditions, enteric hyperoxaluria
after urinary diversion) and bariatric surgery
Sarcoidosis
Spinal cord injury, neurogenic bladder
Genetically determined stone formation
Cystinuria (type A, B and AB)
Primary hyperoxaluria
Renal tubular acidosis type I
2,8-Dihydroxyadeninuria
Xanthinuria
Lesch–Nyhan syndrome
Cystic fibrosis
Drug-induced stone formation
Anatomical abnormalities associated with stone formation
Medullary sponge kidney (tubular ectasia)
UPJ obstruction
Caliceal diverticulum, caliceal cyst
Ureteral stricture
Vesico-uretero-renal reflux
Horseshoe kidney
Ureterocele
Environmental factors
Chronic lead exposure
Table 8 General preventive measures
Fluid intake (drinking
recommendations)
Fluid amount: 2.5–3.0 L/day
Circadian drinking
Neutral pH beverages
Diuresis: 2.0–2.5 L/day
Specific weight of urine: <1010
Nutritional recommendations
for a balanced diet
Balanced diet
Rich in vegetables and fiber
Normal calcium content: 1–1.2 g/day
Limited NaCl content: 4–5 g/day
Limited animal protein content:
0.8–1.0 g/kg/day
Lifestyle recommendations
to normalize general risk
factors
BMI: maintain a normal BMI level
Adequate physical activity
Balance of excessive fluid loss
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improved lithogenic biochemical parameters.280,281 Clinical
studies that utilized magnesium in combination with various
stone inhibitors have shown favorable effects of magnesium
over calcium stone formation,282,283 including increased uri-
nary citrate level and reduced stone recurrence.284 One study
compared the effectiveness of magnesium hydroxide with
chlorthalidone in protection of recurrent calcium nephrolithia-
sis and found inferior results.267 However, one cohort study
of recurrent calcium stone formers reported that increased
magnesium intake was significantly associated with decreased
hyperoxaluria.285
CQ 40. What prevents uric acid stone formation?
• Hydration and urine alkalinization are the mainstays of
uric acid stone prevention. The latter can be achieved
either by diet manipulation or by pharmacotherapy using
citrate supplementation (LE:4, GR:B).
Commentary
The main principles of uric acid stone medical therapy and
prevention are aimed at increasing urine volume, urinary
alkalinization and, less importantly, the reduction of uric acid
excretion.286 The exact amount of daily fluid to prevent uric
acid stone remains unclear. However, a total of 2.5–3 L per
day is generally recommended.287 Urinary alkalinization can
be achieved either by diet manipulation or pharmacotherapy
with the goal of urine pH >6.0.274 Periodic monitoring of
urine pH is mandatory, as hyperalkalinization of urine might
lead to formation of calcium phosphate stones.288
CQ 41. What prevents cystine stones?
• In cystine stone formers, prevention with proper hydration
and urine alkalinization is generally utilized as first-line
prevention. If stone recurrence still occurs, second-line
prevention with a cystine-binding agent is offered (LE:4,
GR:B).
Commentary
As recurrent stone formation is frequently observed in cystin-
uria patients, medical prophylaxis is highly recommended.289
Cystine is poorly soluble at urine pH <7.0, and stone forma-
tion occurs when urinary cystine concentration is >250 mg/
dL.290 Fluid intake should reach at least 4–5 L/day for adult
patients to achieve a urinary cystine concentration <250 mg/
dL.291 In alkalinized urine, potassium citrate is usually pre-
scribed to target urine pH of 7.0–7.5, if not contraindicated.
If these two steps fail to prevent cystine stone recurrence, the
next step is to add a cystine-binding agent, such as tiopronin
or D-penicillamine.292,293
CQ 42. What prevents infectious stones?
• Fluid intake and diet is general recommended (LE:2,
GR:B).
Table 9 Pharmacological substances used for stone prevention: characteristics, specifics and dosage
Agent Rationale Dose Specifics and side-effects Stone type
Alkaline citrates Alkalinization
Hypocitraturia
Inhibition of calcium
oxalate crystallization
5–12 g/day
(14–36 mmol/day)
Children:
0.1–0.15 g/kg/day
Daily dose for alkalinization
depends on urine pH
Calcium oxalate, uric
acid cystine
Allopurinol Hyperuricosuria
Hyperuricemia
100–300 mg/day
Children: 1–3 mg/kg/day
100 mg in isolated hyperuricosuria
Renal insufficiency demands dose
correction
Calcium oxalate, uric acid,
ammonium urate, 2,8-
dihydroxyadenine
Calcium Enteric hyperoxaluria 1000 mg/day Intake 30 min before meals Calcium oxalate
Captopril Cystinuria
Active decrease of urinary
cystine levels
75–150 mg Second-line option due to
significant side effects
Cystine
Febuxostat Hyperuricosuria
Hyperuricemia
80–120 mg/day Acute gout contraindicated,
pregnancy, xanthine stone
formation
Calcium oxalate, uric acid
L-Methionine Acidification 600–1500 mg/day Hypercalciuria, bone
demineralization, systemic
acidosis
No long-term therapy
Infection stones, ammonium
urate, calcium phosphate
Magnesium Isolated hypomagnesiuria
Enteric hyperoxaluria
200–400 mg/day
Children: 6 mg/kg/day
Renal insufficiency demands dose
correction
Diarrhea, chronic alkali losses,
hypocitraturia
Calcium oxalate
Sodium bicarbonate Alkalinization Hypocitraturia 4.5 g/day Calcium oxalate, uric
acid, cystine
Pyridoxine Primary hyperoxaluria Initial dose 5 mg/kg/day
Maximum 20 mg/kg/day
Polyneuropathia Calcium oxalate
Thiazide
(hydrochlorothiazide)
Hypercalciuria 25–50 mg/day
Children: 0.5–1 mg/kg/day
Risk for agent-induced hypotonic
blood pressure, diabetes,
hyperuricemia, hypokalemia,
followed by intracellular acidosis
and hypocitraturia
Calcium oxalate,
calcium phosphate
Tiopronin Cystinuria, active decrease
of urinary cystine levels
Initial dose 250 mg/day
Maximum 2000 mg/day
Risk for tachyphylaxis and
proteinuria
Cystine
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• Other treatments, such as short- or long-term antibiotic
treatment, methionine or ammonium chloride, restricted
intake of urease, or acetohydroxamic acid, might be con-
sidered for recurrent or severe infection (LE:1, GR:A).
• Phytolysin improves general clinical signs and laboratory
parameters of blood and urine, and reduces the number of
relapses of UTI and stone formation (LE:2, GR:B).
Commentary
General preventive measures are recommended for fluid
intake and diet. Specific measures include complete surgical
stone removal (LE:2, GR:B).294 Short- or long-term antibiotic
treatment,295 urinary acidification using methionine (LE:2,
GR:B),296 or ammonium chloride (LE:2, GR:B),297 and
advice to restrict intake of urease (LE:1, GR:A).298,299 For
severe infections, acetohydroxamic acid might be an option
(LE:1, GR:A).298,299 Phytolysin leads to a decrease in the
level of leukocyturia and bacteriuria, increases diuresis and
urinary alkalinization, and reduces the number relapses of
UTI and stone formation (LE:2, GR:B).300
CQ 43. What is a useful imaging test for follow up of uri-
nary stone recurrence?
• Plain radiography, nephrotomography, US, IVU and CT
have all been used to evaluate residual fragments (LE:1,
GR:A).
• The routine use of CT scan for follow-up studies should
be carried out cautiously and only when necessary (LE:1,
GR:A).
• Imaging plays a critical role in the initial diagnosis, follow
up and urological management of urinary tract stone dis-
ease (LE:1, GR:A).
Commentary
A variety of imaging modalities are available to the practicing
urologist, including KUB, IVU, US, magnetic resonance
urography and CT scans, each with its advantages and limita-
tions. Post-treatment imaging of stone patients is recom-
mended to ensure complete fragmentation and stone
clearance. Plain radiography is suggested for the follow up of
radiopaque stones, with US and limited IVU reserved for the
follow up of radiolucent stones to minimize cumulative radia-
tion exposure from repeated CT scans. CT is a modality of
choice for identifying residual stone burden after interven-
tional procedures,301–304 and has a definitive role in the fol-
low up of stones that are lucent on conventional
imaging.301,305 Patients with asymptomatic caliceal stones
who prefer an observational approach should have a yearly
KUB to monitor the progression of stone burden (LE:2,
GR:A).301,303,306
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